

RELEASE OF SECURITIES FROM MANDATORY ESCROW

21 October 2022 - Nutritional Growth Solutions Ltd. (“the Company” or “NGS”, ASX:NGS), a global nutrition company that creates scientifically formulated and clinically proven supplements to support growth development in children and young people, advises, pursuant to ASX Listing rule 3.10A, that the following securities will be released from mandatory escrow on 30 October 2022:

Type of Security	Number of Securities
Fully paid ordinary shares	50,095,953
Unlisted options expiring 23 October 2025	20,000,000
Unlisted options expiring 31 December 2025	6,685,716
Unlisted options expiring 3 January 2029	2,461,286

Nutritional Growth Solutions CEO and Managing Director, Liron Fendell said:

“The large majority of these escrowed shares are owned by our founding shareholders, being Schneiders Medical Centre Israel and connected doctors, and they have advised that they continue to be supportive shareholders and have no intention to sell any of their shares. We thank them for their ongoing support.”

-ENDS-

This announcement has been authorised for release by the Board of Directors of Nutritional Growth Solutions Ltd.

More information:

Liron Fendell, CEO & MD
 Nutritional Growth Solutions Ltd.
liron@ngsolutions.co

Investors

Eric Kuret
 +61 417 311 335

Media

Tristan Everett
 +61 403 789 096

Nutritional Growth Solutions Ltd.
 ARBN 642 861 774
 Israel: 3 Hanechoshet Street, Tel Aviv 6423806
 Australia (Registered Local Agent): C/- Level 5, 126 Phillip Street, Sydney NSW 2000

ASX Code: NGS



eric.kuret@atomicgroup.com.au

tristan.everett@atomicgroup.com.au

About Nutritional Growth Solutions

Nutritional Growth Solutions is a global nutritional health company focused on the well-being of children. NGS develops, produces and sells clinically tested nutritional supplement formulae for children following 20 years of medical research into pediatric nutrition at Schneider Children's Medical Centre, Israel's largest pediatric hospital. The nutritional supplements market has experienced tremendous growth in recent years, but most attention has been focused on adult users and children under three years of age. The three to twelve-year-old consumers represent a larger market opportunity and NGS is highly differentiated from its competitors with clinically tested products and an expanding product portfolio to capture this market opportunity.

ngsolutions.co